192 related articles for article (PubMed ID: 27017207)
1. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.
Kurebayashi J; Toyama T; Sumino S; Miyajima E; Fujimoto T
Breast Cancer; 2017 Jan; 24(1):161-170. PubMed ID: 27017207
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Ohashi Y; Sasai K; Fujimoto T
Breast Cancer; 2016 May; 23(3):499-509. PubMed ID: 25655898
[TBL] [Abstract][Full Text] [Related]
4. Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial.
Ohashi Y; Shiba E; Yamashita H; Kurebayashi J; Noguchi S; Iwase H; Yoshida M; Fujimoto T
Support Care Cancer; 2018 Mar; 26(3):933-945. PubMed ID: 29063390
[TBL] [Abstract][Full Text] [Related]
5. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Kurebayashi J; Shiba E; Toyama T; Matsumoto H; Okazaki M; Nomizu T; Ohtake T; Fujii T; Ohashi Y
Breast Cancer; 2021 May; 28(3):684-697. PubMed ID: 33638810
[TBL] [Abstract][Full Text] [Related]
6. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.
Schmid P; Untch M; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Lehmann U; Maubach L; Meurer J; Wallwiener D; Possinger K
J Clin Oncol; 2007 Jun; 25(18):2509-15. PubMed ID: 17577027
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
8. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
9. [A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
Komura E; Fujimoto T; Takabayashi N; Okamoto H; Akaza H
Gan To Kagaku Ryoho; 2014 May; 41(5):587-93. PubMed ID: 24917003
[TBL] [Abstract][Full Text] [Related]
10. The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress.
Kim HA; Ahn SH; Nam SJ; Park S; Ro J; Im SA; Jung YS; Yoon JH; Hur MH; Choi YJ; Lee SJ; Jeong J; Cho SH; Kim SY; Lee MH; Kim LS; Moon BI; Kim TH; Park C; Kim SJ; Jung SH; Park H; Gwak GH; Kang SH; Kim JG; Kim J; Choi SY; Lim CW; Kim D; Yoo Y; Song YJ; Kang YJ; Jung SS; Shin HJ; Lee KJ; Han SH; Lee ES; Han W; Kim HJ; Noh WC
BMC Cancer; 2016 May; 16():319. PubMed ID: 27197523
[TBL] [Abstract][Full Text] [Related]
11. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review.
Kendzierski DC; Schneider BP; Kiel PJ
Clin Breast Cancer; 2018 Oct; 18(5):e939-e942. PubMed ID: 29747931
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
14. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
16. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
[TBL] [Abstract][Full Text] [Related]
18. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
19. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
20. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
